Tag: Cynata

December 10, 2018

Genetics Outlook 2019: CRISPR Technology Advances

With 2018 coming to a close, here's a look at the biggest genetics trends of the year and what's in...
April 20, 2018

Cynata Therapeutics Completes Patent Application to Cover Cymerus Stem Cell Technology

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that it has completed the filing of a...
March 29, 2018

Cynata Therapeutics Receives Orphan Drug Designation from FDA

The orphan drug designation is a unique mission that incentivizes companies to develop treatments for the rare disease market.
March 28, 2018

FDA Grants Orphan Drug Designation to Cynata’s Lead Cymerus MSC Product, CYP-001

Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the United States Food...
February 27, 2018

Excellent Cohort A Data From Final Primary Evaluation Period in Cynata GvHD Phase 1 Clinical Trial

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary Evaluation Period...
January 24, 2018

Treatment Commences in Second Patient Cohort in Cynata’s World First Clinical Trial

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that the first patient in Cohort B has...
January 23, 2018

Cynata Executes MoU for Commercial Evaluation with Celularity

Australian stem cell and regenerative medicine company, Cynata Therapeutics (ASX:CYP), is pleased to announce that the Company has entered into a...